While still relatively rare, there have been 6,400 cases of multisystem inflammatory syndrome in children (MIS-C) related to COVID-19 in the United States—including 55 deaths—since the pandemic began, according to data from the Centers for Disease Control and Prevention. With records for pediatric and adult infection continuing to be broken on a daily basis in some states and municipalities, it stands to reason that risk for MIS-C could also be increasing. The possibly good news is that the CDC announced that two doses of the Pfizer COVID-19 vaccine, specifically, are estimated to be 91% effective in preventing it in children between 12 and 18 years of age. The data are drawn from assessment of 283 hospitalized patients in 24 children’s facilities in 20 states between July and early December. (The Delta variant was dominant at that time.) Further, the 38 MIS-C patients who required life support were not vaccinated at all. For more on MIS-C from a specifically urgent care perspective, read Multisystem Inflammatory Syndrome in Children (MIS-C): Who Should Not Be MISC’ED? in the JUCM archive.
CDC: One Vaccine May Be Especially Effective in Lowering Risk for MIS-C